Enzon Pharmaceuticals, Inc.
ENZN
$0.0808
-$0.0048-5.61%
OTC PK
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | 0.00 | -- | 26.00K |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | 0.00 | -- | 26.00K |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | 0.00 | -- | 26.00K |
SG&A Expenses | 314.00K | 1.00M | 325.00K | 351.00K | 351.00K |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 314.00K | 1.00M | 325.00K | 351.00K | 351.00K |
Operating Income | -314.00K | -1.00M | -325.00K | -351.00K | -325.00K |
Income Before Tax | -1.03M | -505.00K | 221.00K | 303.00K | 280.00K |
Income Tax Expenses | -42.00K | 19.00K | 293.00K | 49.00K | 4.00K |
Earnings from Continuing Operations | -990.00K | -524.00K | -72.00K | 254.00K | 276.00K |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -990.00K | -524.00K | -72.00K | 254.00K | 276.00K |
EBIT | -314.00K | -1.00M | -325.00K | -351.00K | -325.00K |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 |
Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EPS Diluted | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 |
Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Basic Shares Outstanding | 74.22M | 74.22M | 74.22M | 74.22M | 74.22M |
Average Diluted Shares Outstanding | 74.22M | 74.22M | 74.22M | 74.22M | 74.22M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | 0.00% | -243.32% | 0.00% | 0.00% | 0.00% |